Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook
08 Gennaio 2024 - 1:30PM
Members of management of Surgery Partners, Inc. (NASDAQ:SGRY)
("Surgery Partners" or the "Company"), a leading short-stay
surgical facility owner and operator, will be meeting with
investors today, January 8, 2024, as part of the 42nd Annual J.P.
Morgan Healthcare Conference, including a presentation at 5:15 p.m.
ET. Based on results through November 2023, the Company is
re-affirming its 2023 Adjusted EBITDA guidance of $436 million to
$440 million and its 2023 Revenue guidance of approximately $2.75
billion. Additionally, consistent with managements commitment to
driving mid-teens growth, the Company projects 2024 Adjusted EBITDA
to be greater than $495 million.
Interested investors and other parties may listen to a
simultaneous webcast of the event by logging onto the Investor
Relations section of the company's website at
www.surgerypartners.com. The replay will also be available on this
same website for a limited time following the call.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery
Partners is a leading healthcare services company with a
differentiated outpatient delivery model focused on providing
high-quality, cost-effective solutions for surgical and related
ancillary care in support of both patients and physicians. Founded
in 2004, Surgery Partners is one of the largest and fastest
growing surgical services businesses in the country, with more than
180 locations in 32 states, including ambulatory surgery centers,
surgical hospitals, multi-specialty physician practices and urgent
care facilities. For additional information,
visit www.surgerypartners.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including those regarding growth and our anticipated operating
results for future periods and other similar statements. These
statements can be identified by the use of words such as
"believes," "anticipates," "expects," "intends," "plans,"
"continues," "estimates," "predicts," "projects," "forecasts,"
"may," "could," and similar expressions. All forward-looking
statements are based on current expectations and beliefs as of the
date of this release and are subject to risks, uncertainties and
other factors that may cause actual results to differ materially
from the expectations discussed in, or implied by, the
forward-looking statements. Many of these factors are beyond our
ability to control or predict including, without limitation,
reductions in payments from government health care programs and
private insurance payors, such as health maintenance organizations,
preferred provider organizations, and other managed care
organizations and employers; our ability to contract with private
insurance payors; changes in our payor mix or surgical case mix;
failure to maintain or develop relationships with physicians on
beneficial or favorable terms, or at all; the impact of payor
controls partners, or acquire additional surgical facilities;
supply chain issues, including shortages or quality control issues
with surgery-related products, equipment and medical supplies;
competition for physicians, nurses, strategic relationships,
acquisitions and managed care contracts; our ability to attract and
retain qualified health care professionals; our ability to enforce
non-compete restrictions against our physicians; our ability to
manage material liabilities whether known or unknown incurred as a
result of acquiring surgical facilities; the impact of future
legislation and other health care regulatory reform actions, and
the effect of that legislation and other regulatory actions on our
business; our ability to comply with current health care laws and
regulations; the outcome of legal and regulatory proceedings that
have been or may be brought against us; the impact of cybersecurity
attacks or intrusions, changes in the regulatory, economic and
other conditions of the states where our surgical facilities are
located; our indebtedness; the social and economic impact of a
pandemic, epidemic or outbreak of a contagious disease, such as
COVID-19, on our business; and the risks and uncertainties
identified and discussed from time to time in the Company’s reports
filed with the SEC, including in Item 1A under the heading "Risk
Factors" in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022. Except as required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements to reflect events or circumstances after
the date of this report, or to reflect the occurrence of
unanticipated events or circumstances.
In addition, the guidance for the fiscal year ended December 31,
2023 is based on results of the Company through November 2023 and
is subject to quarter- and year-end adjustments in connection with
the completion of customary financial closing procedures, including
management’s review and finalization of the results for the full
year 2023 and to audit procedures by the Company’s independent
registered public accounting firm, which have not yet been
performed. These customary closing procedures, along with December
results, could cause actual results to differ materially from
management’s guidance. You are cautioned not to rely on
management’s guidance being achieved when making an investment
decision in the Company’s securities.
Contact:
Surgery Partners Investor Relations (615)
234-8940IR@surgerypartners.com
Grafico Azioni Surgery Partners (NASDAQ:SGRY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Surgery Partners (NASDAQ:SGRY)
Storico
Da Feb 2024 a Feb 2025